AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Über uns

Führendes Medizintechnik-Unternehmen, das sich auf orthopädische Implantate, chirurgische Ausrüstung und neurovaskuläre Geräte spezialisiert. Das Mako-Roboterarm-Chirurgiesystem treibt Innovation an.

Aktienbestände für alternde Bevölkerung

Stryker ist ein führendes medizintechnisches Unternehmen, das auf orthopädische Implantate, chirurgische Ausrüstung und neurovaskuläre Geräte spezialisiert ist, die weltweit zunehmend benötigt werden, wenn Bevölkerungen altern.

Key Financials SYK

Preis $366.05
Veränderung (1T) +0.05%
52-Wochen-Spanne $329.16 — $404.87
Volumen 2.34M

Data updated Feb 15 · Source: Twelve Data

4.7
1 reviews
Demographic Exposure
5
Growth Potential
4.7
Financial Stability
4.5
Dividend Reliability
3.8
Regulatory Risk
3.5
Claude Opus 4.6
AI Review
4.7/5

Stryker Corporation is a premier medical technology company specializing in orthopedic implants, surgical equipment, and neurotechnology " product lines directly aligned with aging population demographics. As joint replacements, spinal surgeries, and hospital procedures increase with an older global population, Stryker stands to benefit from durable, secular tailwinds.

Financially, Stryker demonstrates consistent revenue growth, strong margins, and a track record of accretive acquisitions (notably Wright Medical and MAKO Surgical). The company's robotic-assisted surgery platform (Mako) provides a competitive moat and positions it well against peers like Zimmer Biomet and Medtronic. Trading near $366, the stock sits roughly 10% below its 52-week high, potentially offering a reasonable entry point, though its premium valuation (typically 25-30x forward earnings) demands continued execution.

Bull case: Irreversible demographic trends, innovation leadership in robotics, and pricing power. Bear case: Elevated valuation, potential hospital spending slowdowns, and integration risks from acquisitions. Stryker remains one of the strongest pure-play investments on global aging, combining quality management with a defensible market position.

Demographic Exposure
5
Growth Potential
4.7
Financial Stability
4.5
Dividend Reliability
3.8
Regulatory Risk
3.5
Feb 15, 2026
Stryker Corporation Screenshot

Added: Feb 15, 2026

stryker.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

So backtesten Sie eine Handelsstrategie: Methoden, Fallstricke und was die Ergebnisse tatsächlich bedeuten

So backtesten Sie eine Handelsstrategie: Methoden, Fallstricke und was die Ergebnisse tatsächlich bedeuten

Jeder Trader hat eine Strategie, die in seinem Kopf großartig aussieht. Backtesting ist die Art herauszufinden, ob sie tatsächlich funktioniert. Hier erfahren Sie, wie Sie Strategien richtig testen, welche Kennzahlen wichtig sind und warum die meisten Backtest-Ergebnisse zu gut sind, um wahr zu sein.